RxDoctor Payments Data

David Schnapp, MD

Urology · Auburn, NYNPI 1609970854

Payments from drug & device makers

$4,447in general payments, 2019–2025

Across 214 payments — averaging $20.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$447
  • Myriad Genetic Laboratories, Inc.$442
  • AbbVie$353
  • Johnson & Johnson$335
  • Astellas Pharma US Inc$322
  • Teleflex LLC$321
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,23595%
  • Education$2135%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,447 in reported general payments places this provider in the 60th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$408,215
Medicare patients
874
Services billed
11,667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron65$64,455
MyrbetriqMirabegron26$23,549
Testosterone13$3,324
Tamsulosin Hcl268$3,062
Potassium Citrate ErPotassium Citrate13$1,436
Finasteride128$1,425
Alfuzosin Hcl ErAlfuzosin Hcl80$1,335
Oxybutynin Chloride ErOxybutynin Chloride58$1,131
Dutasteride15$424
Ciprofloxacin Hcl128$422
Triamcinolone Acetonide25$391
Nystatin30$383
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim53$173
Doxycycline Hyclate20$135
Amoxicillin79$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$213$64,45565 claims
Astellas Pharma US IncMyrbetriq$322$23,54926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 952 urology providers in New York.

Other urology in Auburn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →